# Ernexa Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Ernexa Therapeutics Inc.). ## Overview Ernexa Therapeutics Inc. is a preclinical-stage cell therapy company developing synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cell) therapies. Its lead program, ERNA-101, is designed to deliver immune-stimulating cytokines into the tumor microenvironment, with an initial focus on platinum-resistant ovarian cancer and a broader pipeline in autoimmune disease. ## Products & services • ERNA-101: IL-7 and IL-15-secreting iMSC cancer therapy • ERNA-201: IL-10-secreting iMSC program for autoimmune disease • Preclinical cell line development and customization services • Strategic licensing / out-licensing of therapeutic assets • Research collaborations and non-dilutive grant-funded R&D - **Lead therapeutic programs** (0%) — Preclinical cell therapy candidates designed to modulate immune responses in cancer and autoimmune disease. - **Cell line customization services** (100%) — Custom development of induced pluripotent stem cell lines for a customer under a contract arrangement. - **Licensing and collaboration arrangements** (0%) — Option, sublicense, and partnership structures intended to monetize platform technology and future assets. - **Research and development services** (0%) — Preclinical research, assay development, and partner-supported development activities. - ERNA-101: IL-7 and IL-15-secreting allogeneic iMSC therapy - ERNA-201: anti-inflammatory IL-10-secreting iMSC program - Preclinical iPSC-derived cell line customization work - Licensing and out-licensing of iMSC-based therapeutic assets - Research collaborations with academic and industry partners - Grant-supported R&D, including work through Ernexa TX2, Inc. ## Customers Ernexa’s direct customers have been limited and contract-based, including a customer for exclusive option/licensing rights and cell line customization work. More broadly, its future customers are likely to be pharmaceutical partners, biotech collaborators, and clinical or commercial licensees rather than end patients, since the company is still preclinical and not yet selling approved therapies. - **Pharmaceutical and biotechnology partners** (primary) — Potential licensees or co-development partners that would pay for access to the iMSC platform and pipeline assets. - **Custom cell line customer** (secondary) — A contract customer that paid for iPSC line customization and related option/licensing rights. - **Academic research collaborators** (secondary) — Institutions such as MD Anderson that support preclinical validation and translational work. - **Grant and non-dilutive capital providers** (emerging) — Public or private funding sources that support research activities and reduce dilution. - Biotech or pharma partners seeking access to iMSC platform technology - Customers buying customized iPSC-derived cell lines for development work - Potential sublicensees of ERNA-101 or related therapeutic assets - Academic or translational collaborators supporting preclinical studies - Grant and non-dilutive funding sources supporting research programs ## Geography Ernexa is headquartered in the United States and appears to conduct most of its operations there, including research activity through its Texas subsidiary. The company is also building an international development path, highlighted by participation in a Japan External Trade Organization acceleration program to support future market entry and collaboration in Japan. - United States is the core operating base and corporate headquarters - Texas subsidiary supports research activity and grant-funded work - Japan is a strategic target for future clinical and commercial entry - No disclosed country revenue mix; company currently has no ongoing revenue contracts - Geographic exposure is mainly operational and regulatory, not sales-driven ## Strategy The company’s near-term strategy is to advance ERNA-101 through IND-enabling work, submit an IND in 2026, and begin a Phase I investigator-sponsored trial in the second half of 2026. It is also seeking strategic partnerships, out-licensing opportunities, and research grants to fund development while preserving capital. - **Advance ERNA-101 into clinical testing** (short-term) — Clinical entry is the key value inflection point for a preclinical biotech and validates the platform beyond lab data. - **Secure external funding and partnerships** (short-term) — The company has stated it lacks sufficient capital for the next 12 months and needs non-dilutive or dilutive funding to continue operations. - **Build a broader iMSC pipeline** (medium-term) — A second program such as ERNA-201 can broaden the platform beyond oncology and improve partnering appeal. - Complete IND-enabling studies and submit ERNA-101 IND in 2026 - Advance first-in-human testing in platinum-resistant ovarian cancer - Use preclinical data to support platform credibility and partnering - Pursue out-licensing and co-development to monetize the pipeline - Raise non-dilutive capital through grants and collaborations - Expand optionality through Japan market-entry and partnership work ## Risks Ernexa is a development-stage biotech with no commercial product revenue and a stated going-concern risk, so financing execution is central to survival. Its programs also face high clinical, regulatory, and competitive uncertainty, especially in ovarian cancer where larger companies and approved therapies already compete for physician and payer attention. - **Insufficient capital to fund operations** [critical] — Management disclosed it will not have sufficient capital for the next 12 months without additional financing. - **Clinical development failure** [high] — ERNA-101 is preclinical and may fail in IND-enabling studies, human trials, or later efficacy testing. - **Competitive displacement in ovarian cancer** [high] — Approved and late-stage therapies may reach the market before Ernexa, limiting adoption and pricing power. - **Nasdaq continued listing compliance** [medium] — The company disclosed risk of delisting if it fails minimum bid price or equity requirements. - Going-concern risk if additional capital is not raised on time - Clinical failure risk because ERNA-101 is still preclinical - Regulatory risk around IND clearance and cell therapy requirements - Competition from larger biotech and pharma companies with more resources - Nasdaq listing risk if stock price or equity thresholds are not met - Limited revenue base increases dependence on financing and partnerships ## Accounting Revenue recognition is highly contract-specific and currently minimal, with the company stating it had no revenue-generating contracts in 2025 after assigning its customer contract to Factor Bioscience. The financial statements also depend heavily on estimates for goodwill impairment, fair value measurements, and debt-related instruments, which can materially affect reported earnings and balance sheet values in a small, loss-making biotech. - **Revenue recognition on customization and licensing contracts** — Affects reported revenue and cost of revenues - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Goodwill impairment** — Could create non-cash charges and reduce equity - **Fair value of debt and equity-linked instruments** — Can materially affect net loss and volatility - Revenue was tied to a single customization contract and then ceased - Assignment agreement changed future revenue and cost recognition - R&D is expensed as incurred, so pipeline spending hits earnings immediately - Goodwill impairment testing is judgmental and sensitive to stock price - Fair value changes on notes, warrants, and derivatives can swing results - Going-concern assessment affects disclosure and investor interpretation --- *Last updated: 2026-04-28T20:05:20.530706+00:00*